The role of interferon in the new era of hepatitis C treatments

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 6, 2014, Pages 649-656

  Parekh, Parth J ^a   Shiffman, Mitchell L ^a,b,c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Bon Secours Health System   (United States)

^c Bon Secours Health System   (United States)

Author keywords

chronic hepatitis C virus; IL28B; interferon; response guided therapy

Indexed keywords

ABT 450; ACH 1625; ACH 3102; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; DELEOBUVIR; FALDAPREVIR; INTERFERON; INTERLEUKIN 28B; MK 5127; MK 8742; OMBITASVIR; PEGINTERFERON; PEGINTERFERON LAMBDA; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; MENTAL DISEASE; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; ANIMAL; DRUG COMBINATION; DRUG DESIGN; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; REMISSION; TREATMENT OUTCOME;

ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84904469564     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.910453     Document Type: Review

References (47)

1. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10
2. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-6
3. Mchutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92
4. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
5. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
6. Poordad F, Mccone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
7. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
8. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013;58:1918-29
9. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
10. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368: 1867-77
11. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection [abstract LB-1]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012); 9-13 November 2012; Boston, MA, USA
12. Everson GT, Sims KD, Thuluvath PJ, et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection [abstract LB-2]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 1-5 November 2013; Washington, DC, USA
13. Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir/ledipasvir fixed dose. combination with or without ribavirin: The ELECTRON trial. Hepatology 2013. 58(Suppl):243A
14. Dufour J, Buti M, Soriano V, et al. Interferon-free treatment with faldaprevir, deleobuvir (BI 207127) and ribavirin in SOUND-C3: 95% SVR12 in HCV-GT1b. Hepatology 2013;58(Suppl):744A
15. Lalezari J, Holland L, Glutzer E, et al. Rapid and consistent virologic responses in a phase 2 trial of a new all-oral combination of faldaprevir, deleobuvir, and PPI-668, with and without ribavirin, in patients with HCV Genotype-1a infection [abstract LB-20]. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 1-5 November 2013; Washington, DC, USA
16. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809
17. Bekisz J, Schmeisser H, Hernandez J, et al. Human interferons alpha, beta and omega. Growth Factors 2004;22:243-51
18. Müller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-21
19. Ank N, Iversen MB, Bartholdy C, et al. An important role for type III interferon (IFNlambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008;180:2474-85
20. Samuel CE, Kuhen KL, George CX, et al. The PKR protein kinase-An interferon-inducible regulator of cell growth and differentiation. Int J Hematol 1997;65: 227-37
21. Witt PL, Marié I, Robert N, et al. Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. J Interferon Res 1993;13:17-23
22. Haller O, Stertz S, Kochs G. The Mx GTPase family of interferon-induced antiviral proteins. Microbes Infect 2007;9: 1636-43
23. Rehermann B. Chronic infections with hepatotropic viruses: Mechanisms of impairment of cellular immune responses. Semin Liver Dis 2007;27:152-60
24. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52:822-32
25. Muir AJ, Hillson JL, Gray TE, et al. Peginterferon lambda-1a (lambda) compared to peginterferon alfa-2a (alfa) in treatment-naive patients with HCV genotypes (GT) 1 or 4: SVR24 results from EMERGE Phase 2b. Hepatology 2012; 56(Suppl):299A
26. Muir AJ, Srinivasan S, Sapra S, et al. Peginterferon lambda-1a (lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa). Hepatology 2012;56(Suppl):578A
27. Fredlund P, Hillson JL, Gray TE, et al. Peginterferon lambda-1a (lambda) is associated with less autoimmune thyroid disease and serious autoimmune disease than peginterferon alfa-2a (alfa) when used in combination with ribavirin (RBV) for the treatment of chronic hepatitis C virus infection. Hepatology 2012;56(Suppl):571A
28. Shiffman ML. Interferon-free regimens: The near future, the likely and the not so likely. Clin Liver Dis 2011;15:665-75
29. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34
30. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9
31. Rao HY, Sun DG, Jiang D, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 2012;19(3): 173-81
32. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
33. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology 2011;53: 336-45
34. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801
35. Manns M, Marcellin P, Poordad FPF, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin for the treatment of chronic HCV genotype-1 infection in treatment-naïve patients: Results from QUEST-2, a phase 3 trial. J Hepatol 2013; 58(suppl):Abstract 1413
36. Shiffman ML. HCV response guided therapy: Should treatment length be shortened or extended?. Curr Hepatitis Rep 2011;10:4-10
37. Bronowicki J-P, Hezode C, Bengtsson L, et al. 100% SVR in IL28B SNP rs12979860 C/C patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial. J Hepatol 2012;56(Suppl 2):S430-1
38. Nelson DR, Poordad F, Feld JJ, et al. High SVR rates for 12-week total telaprevir combination therapy in IL28B CC treatment-naïves and prior relapsers with G1 chronic hepatitis C: CONCISE interim analysis. J Hepatol 2013;58(Suppl 1):S362
39. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013;57:2143-54
40. Sulkowski MS, Bourlière M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013;57: 2155-63
41. Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol 2004;3:5-10
42. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013;59: 434-41
43. Gale M, Katze MG. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon induced protein kinase. Pharmacol Ther 1998;78:29-46
44. Taylor DR, Shi ST, Romano PR, et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-10
45. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: The VALENCE trial. Hepatology 2013; 58(Suppl):733A
46. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in combination with pegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: Results from the LONESTAR-2 study [abstract LB-4]. 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1-3 November 2013; Washington, DC, USA
47. Lyoo K, Song MJ, Hur W, et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 2011;52:363-6